Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $15.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 17.37% year-over-year to $15.8 million, compared with a TTM value of $58.7 million through Sep 2025, down 2.83%, and an annual FY2024 reading of $14.9 million, down 9.6% over the prior year.
  • Liabilities and Shareholders Equity was $15.8 million for Q3 2025 at China Pharma Holdings, up from $13.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $22.6 million in Q4 2021 and bottomed at $13.5 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $16.9 million, with a median of $16.2 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 21.48% in 2022, then increased 17.37% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then dropped by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then rose by 6.16% to $15.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CPHI at $15.8 million in Q3 2025, $13.8 million in Q2 2025, and $14.2 million in Q1 2025.